covid
Buscar en
Angiología
Toda la web
Inicio Angiología Injertos suprageniculares con politetrafluoroetileno. Factores que pueden influi...
Journal Information
Vol. 54. Issue 4.
Pages 317-326 (January 2002)
Share
Share
Download PDF
More article options
Vol. 54. Issue 4.
Pages 317-326 (January 2002)
Full text access
Injertos suprageniculares con politetrafluoroetileno. Factores que pueden influir en su permeabilidad
Above knee polytetrafluoroethylene grafts. factors that may influence patency
Enxertos supra-geniculares de politetrafluoroetileno. factores que influenciam a sua permeabilidade
Visits
3138
E. Herández-Osma
Corresponding author
mcairols@csub.scs.es

correspondence: Servicio de Angiología y Cirugía Vascular. Hospital Universitari de Bellvitge. Feixa Llarga, s/n. E-08907 L'Hospitalet de Ll. (Barcelona).
, M.A. Cairols, J.M. Simeón, S. Riera, X. Martí, F. Guerrero
Servicio de Angiología y Cirugía Vascular. Hospital Universitari de Bellvitge. L'Hospitalet de Ll. (Barcelona), España.
This item has received
Article information
Summary
Objective

To assess possible factors that may have some influence in above-knee polytetrafluoroethylene (PTFE) femoropopliteal grafts patency.

Patients and methods

One hundred above-knee femoropopliteal grafts were carried out in 98 patients (77 male and 21 female, with a mean age of 69 years; r= 49-90). In 90 cases surgery was performed for critical limb ischaemia and in 10 for intermittent claudication. Retrospective observational study, with a mean follow-up of 5 years. The following parameters were evaluated: age (older or younger 65 years), gender, cardiovascular risk factors, ankle/brachial index pressure, run-off capabilities (distal anastomotic vessels patency), fibrinogen (above and bellow the mean of 5.7g/L) and blood cell count: hematocrit< 45%, leukocytes< 10,000 and platelets< 250,000. Cox regression and Kaplan-Meier was used for statistical analysis.

Results

The 30 days postoperative patency was of 99%, and the cumulative at 1, 2 and 5 years was 75, 56 and 41%, respectively. Patency at 18 months was 67%, which means that 75% of all occlusion were produced along the first 18 months of the postoperative period. In this period of 18 months only fibrinogen and blood cellularity were statistical significant (p< 0.05). The same parameters at 5 years shows differences according to distal outflow (p= 0.01), fibrinogen (p= 0.001) and blood cellularity (p= 0.001). Secondary late patency rate was of 41% and the limb salvage rate of 82% at 5 years.

Conclusion

Raised fibrinogen and blood cellularity may influence negatively in keeping above-knee PTFE grafts patent.

Key words:
Above-knee by-pass
Blood cellularity
Critical ischaemia
Fibrinogen
Intermittent claudication
Limb salvage
PTFE
Resumen
Objetivo

Identificar posibles factores relacionados con la oclusión de los injertos suprageniculares de politetrafluoroetileno (PTFE).

Pacientes y métodos

Estudio de 100 injertos femoropoplíteos suprageniculares de PTFE realizados en 98 pacientes (77 varones y 21 mujeres, con una edad media de 69 años; intervalo: 49-90 años). En 90 casos se indicó la revascularización por isquemia crítica de la extremidad y en 10 por claudicación intermitente. Estudio observacional retrospectivo durante un período de cinco años. Se evaluaron los parámetros siguientes: edad (mayor o menor de 65 años), sexo, factores de riesgo cardiovasculares, índice tobillo/brazo, salida distal, fibrinógeno (superior o inferior a la media de 5,7g/ L) y celularidad sanguínea: hemato-crito <45%, leucocitos <10.000 y plaquetas <250.000. Para el análisis estadístico se utilizó la regresión multivariante de Cox y tablas de vida Kaplan-Meier.

Resultados

La permeabilidad a los 30 días fue del 99%, y la acumulativa a 1, 2 y 5 años fue del 75, 56 y 41%, respectivamente. El 75% de las oclusiones se produjeron en los primeros 18meses (permeabilidad del 67%). En este período de 18 meses el único factor predictivo de oclusión de los injertos fue el fibrinógeno y la celularidad sanguínea (p< 0,05). A los cinco años los factores predictivos de oclusión fueron la salida distal (p= 0,01), fibrinógeno (p= 0,001) y celulari-dad sanguínea (p= 0,001). La permeabilidad secundaria fue del 41% y el salvamento de extremidad del 82% a los cinco años.

Conclusión

Cifras altas de fibrinógeno y celularidad sanguínea influyen negativamente en la permeabilidad de los injertos suprageniculares de PTFE.

Palabras clave:
Celularidad sanguínea
Claudicación intermitente
Fibrinógeno
Injerto supragenicular
Isquemia crítica
PTFE
Salvamento extremidad
Resumo
Objectivo

Identificar possíveis factores relacionados com a oclusao dos enxertos suprageniculares de politetrafluoroetileno (PTFE). Doentes e métodos. Estudo de 100 enxertos femoropoplíteos supra-geniculares de PTFE realizados em 98 doentes (77 homens e 21 mulheres com idade média de 69 anos; intervalo: 49-90 anos). Em 90 casos iniciou-se a revascularizacão por isquemia crítica da extremidade e em 10 por claudicação intermitente. Estudo observacional retrospectivo durante um período de 5 anos. Avaliaram-se os seguintes parámetros: idade (maior ou menor que 65 anos), sexo, factores de risco cardiovasculares, índice maléolo/braço, saída distal, fibrinogénio (superior ou inferior à média: 5,7g/L) e contagem celular, hematócrito <45%, leucócitos <10.000 e plaquetas >250.000. Para a análise estatística utilizou-se a regressão multivariante de Cox e tabelas de vida de Kaplan-Meier.

Resultados

A permeabilidade aos 30 dias foi de 99%, e a acumulada a um, dois e cinco anos, de 75, 56 e 41%, respectivamente. 75% das oclusões ocorreram nos primeiros 18 meses (permeabilidade de 67%). Neste período de 18 meses, o único factor premonitor de oclusão dos enxertos foi o fibrinogénio e ohemograma (p>0,05). Aos 5 anos, os factores premonitores de oclusão foram a saída distal (p=0,01), fibrinogénio (p=0,001) e hemograma (p=0,001). A permeabilidade secundária foi de 41% e o recuperação da extremidade de 82% aos cinco anos.

Conclusão

Valores elevados de fibrinogénio e hemograma influem negativamente na permeabilidade dos enxertos supra-geniculares de PTFE.

Palavras chave:
Hemograma
Claudicação intermitente
Fibrinogénio
Enxerto supragenicular
Isquemia crítica
PTFE
recuperação da extremidade
Full text is only aviable in PDF
Bibliografía
[1.]
Matsumoto H., Hasegawa T., Fuse K., Yamamoto M..
A new vascular prosthesis for a small calibre artery.
Surgery, 74 (1973), pp. 519-523
[2.]
Campbell C.D., Brooks D.H., Webster M.W., Bahson H.T..
The use of expanded microporus polytetrafluoroethylene for limb salvage: a preliminary report.
Surgery, 79 (1976), pp. 485-491
[3.]
Plecha E.J., Freischlag J.A., Seabrook G.R., Townw J.B..
Femoropopliteal bypass revisited: an analysis of 138 cases.
Cardiovasc Surg., 4 (1996), pp. 195-199
[4.]
Abbot W.M., Green R.M., Matsumoto T., Wheeler J.R., Miller N., Veith F.J., et al.
Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial.
Above-knee femoropopliteal study group. J Vasc Surg., 25 (1997), pp. 19-28
[5.]
Rosenthal D., Evans R.D., McKinsey J., Seagraves M.A., Lamis P.A., Clark M.D., Daniel W.W..
Prosthetic above-knee femoropopliteal bypass for intermittent claudication.
J Cardiovasc Surg., 31 (1990), pp. 462-468
[6.]
Allen B.T., Reilly J.M., Rubin B.G., Thompson R.W., Anderson C.B., Flye M.W., et al.
Femoropopliteal bypass for claudication: vein vs PTFE.
Ann Vasc Surg., 10 (1996), pp. 178-185
[7.]
Woratyla S.P., Darling R.C., Chang B.B., Paty P.S., Kreienberg P.B., Leather R.P., et al.
The performance of femoropopliteal bypass using polytetrafluoroethylene.
Am J Surg., 174 (1997), pp. 169-172
[8.]
Veterans Administration Study Group 141.
Comparative evolution of prosthetic, reversed and in situ bypass grafts in distal popliteal and tibial-peroneal vascularization.
Arch Surg., 123 (1988), pp. 434-438
[9.]
Veith F.J., Gupta S.K., Ascer E., White-Flores S., Samson R.H., Scher L.A., et al.
Six year prospective multicenter randomised comparison of autologous saphenous vein and expanded politetrafluoroethylene grats in infra-inguinal arterial reconstructions.
J Vasc Surg., 3 (1986), pp. 104
[10.]
Second European Consensus Document on Chronic Critical Leg ischemia.
Eur J Vasc Surg., 6 (1992), pp. 1-32
[11.]
Whittemore A.D., Clowes A.W., Couch N.P., Mannick J.A..
Secondary femoropopliteal reconstruction.
Ann Surg., 193 (1981), pp. 35-42
[12.]
O'Malley M.K..
Intimal hyperplasia.
Eur J Vasc Surg., 6 (1992), pp. 343-345
[13.]
Clowes A.W..
Intimal hyperplasia and graft failure.
Cardiovasc Pathol, 2 (1993), pp. 179-186
[14.]
Dormandy J.A..
The influence of blood viscosity on blood flow and the effect of low molecular weight Dextran.
Br Med J, 4 (1971), pp. 716-719
[15.]
Rutherford R.B..
Practical ways to improve the patency of infrainguinal bypass.
Current critical problems in vascular surgery, pp. 73-81
[16.]
Rodríguez L., García A., Barba A., Estallo L..
Antiagregantes plaquetarios.
Novedades farmacológicas en las vasculopatías, pp. 75-100
[17.]
Donaldson D.R., Salter M.C.P., Kester R.C..
The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts.
Vasc Surg., 19 (1985), pp. 224-230
[18.]
Kretschmer G., Herbst F., Prager M., Sautner T., Wenzl E., Berlakovich G.A., et al.
A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis.
Arch Surg., 127 (1992), pp. 1112-1115
[19.]
Towne J.B..
Anticoagulation to prolong lower limb bypass graft patency.
The durability of vascular and endovascular surgery, pp. 207-215
[20.]
Fareed J., Walenga J.M., Hoppensteadt D..
Pharmacological profile low molecular weight heparins: implications in prophylaxis and the treatment of thrombotic disorders.
Low molecular weight heparins in clinical practice, pp. 63-84
[21.]
Ehrly A.M..
Drugs that alter blood viscosity.
Their role in therapy. Drugs, 39 (1990), pp. 155-159
[22.]
Porter J., Cutler B., Lee B., Reich T., Reichle F.A., Scogin J.T., Strandness D.E..
Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled doubleblind trial with objective assessment of chronic occlusive arterial disease patients.
Am Heart J, 104 (1982), pp. 66-72
[23.]
Wiseman S., Kenchington G., Dain R., Marshall C.E., McCollum C.N., Greenhalgh R.M., Powell J.T..
Influence of smoking and plasma factors on patency of femoropopliteal vein grafts.
Br Med J, 299 (1989), pp. 643-646
Copyright © 2002. SEACV
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos